← Leaderboards
Jorge A Marrero
University Of Michigan At Ann Arbor
$3,014,574
Attributed
$7,074,609
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,074,609 · 6
By mechanism
U01$3,730,583 · 1
R01$2,524,195 · 1
K23$661,500 · 1
R03$150,480 · 1
M01$7,851 · 2
Top collaborators
- Anand S Mehta5 shared
- Fasiha Kanwal4 shared
- Neehar Dilip Parikh4 shared
- Amit Singal4 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- David M. Lubman$15,307,348
- Laura Beretta$16,561,253
- Neehar Dilip Parikh$2,316,206
- Amy M. Kilbourne$14,622,421
- Brian David Athey$25,019,937
Others in their field
Top investigators on “Early Diagnosis”
- Michael W Weiner · Northern California Institute Res &Educ$162,576,753
- Mitchell D Schnall · University Of Pennsylvania$148,421,012
- David Heimbrook · Leidos Biomedical Research, Inc.$98,656,722
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$85,695,840
- Sharon A Nachman · Johns Hopkins University$77,262,665
- Peter J O'Dwyer · University Of Pennsylvania$75,791,391
Research focus
Early DiagnosisMalignant Neoplasm Of LiverBiological MarkersMalignant NeoplasmsProspectivePrimary Carcinoma Of The Liver CellsCohortTumorCirrhosisDiagnosticEvaluationValidationAlpha-FetoproteinsImageDesignSamplingSerumDetectionAreaPerformanceBiomarker PanelBlindedEarly Detection BiomarkersBlood
Grant awards (18)
Clinical Validation Center for Hepatocellular Carcinoma$893,833
U01 · FY2025 · CA
Clinical Validation Center for Hepatocellular Carcinoma$1,007,940
U01 · FY2024 · CA
Clinical Validation Center for Hepatocellular Carcinoma$1,041,376
U01 · FY2023 · CA
Translation of a biomarker panel for the early detection of hepatocellular carcinoma$405,980
R01 · FY2023 · CA
Clinical Validation Center for Hepatocellular Carcinoma$787,434
U01 · FY2022 · CA
Translation of a biomarker panel for the early detection of hepatocellular carcinoma$521,077
R01 · FY2022 · CA
Translation of a biomarker panel for the early detection of hepatocellular carcinoma$531,711
R01 · FY2021 · CA
Translation of a biomarker panel for the early detection of hepatocellular carcinoma$518,911
R01 · FY2020 · CA
Translation of a biomarker panel for the early detection of hepatocellular carcinoma$546,516
R01 · FY2019 · CA
Complications of Cirrhosis in American Patients$132,300
K23 · FY2008 · DK · contact PI
Early Detection and Prognosis of Patients with Hepatocellular Carcinoma$74,480
R03 · FY2008 · DK · contact PI
Complications of Cirrhosis in American Patients$132,300
K23 · FY2007 · DK · contact PI
Early Detection and Prognosis of Patients with Hepatocellular Carcinoma$76,000
R03 · FY2007 · DK · contact PI
STUDY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLUL$227
M01 · FY2007 · RR · contact PI
Complications of Cirrhosis in American Patients$132,300
K23 · FY2006 · DK · contact PI
Complications of Cirrhosis in American Patients$132,300
K23 · FY2005 · DK
Complications of Cirrhosis in American Patients$132,300
K23 · FY2004 · DK
Treatment of Hepatocellular Carcinoma w/ Tetrathiomolybdate (UMCC 0040)$7,624
M01 · FY2004 · RR